6533b853fe1ef96bd12ac0f9
RESEARCH PRODUCT
Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21st century
Janick WeberpalsDianne PulteLina JansenSabine LuttmannBernd HolleczekAlice NenneckeMeike RessingAlexander KatalinicMaximilian MerzHermann BrennerGekid Cancer Survival Working Groupsubject
AdultMalePathologymedicine.medical_specialtyAdolescentPopulationImproved survivalLymphoplasmacytic Lymphoma03 medical and health sciencesYoung Adult0302 clinical medicineGermanymedicineHumansRegistrieseducationOnline Only ArticlesMultiple myelomaAgededucation.field_of_studybusiness.industryHematologyMiddle Agedmedicine.diseaseUnited StatesSurvival Rate030220 oncology & carcinogenesisPopulation SurveillanceFemaleWaldenstrom MacroglobulinemiabusinessSolitary plasmacytoma030215 immunologyPlasmacytomaSEER Programdescription
Population-level survival has increased for a number of hematologic malignancies.[1][1]–[3][2] Multiple myeloma, in particular, has seen improved survival both in clinical trials[4][3]–[8][4] and on the population level.[3][2],[9][5]–[11][6] However, it is not known whether the changes in
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2017-03-09 |